| COVID-19 Vax Efforts Aim to Balance Speed, Efficacy in Race to Market | Sarah de Crescenzo | 04/17/20 | National |
| Bio Roundup: Alnylam’s Billions, COVID-19 Vaccines, Moma Debuts & More | Sarah de Crescenzo | 04/17/20 | National |
| UroGen Gets FDA Nod for Low-Grade Upper Tract Urothelial Cancer Drug | Sarah de Crescenzo | 04/15/20 | New York |
| GSK and Sanofi Team Up on COVID-19 Vaccine, Aim for Clinic This Year | Frank Vinluan | 04/14/20 | National |
| Blackstone Pays Alnylam $1B to Grab a Stake in RNAi Drug Inclisiran | Frank Vinluan | 04/13/20 | Boston |
| Biotech Roundup: GSK’s Ante, Shakeup at Sage, Telehealth’s Rise & More | Frank Vinluan | 04/10/20 | National |
| Pfizer, BioNTech Say mRNA COVID-19 Vaccine Trials May Start This Month | Frank Vinluan | 04/09/20 | National |
| Roche Pays $190M to Start RNA Drug Alliance With Arrakis Therapeutics | Frank Vinluan | 04/08/20 | Boston |
| Keros Therapeutics Raises $96M in Upsized IPO to Fuel Clinical Tests | Sarah de Crescenzo | 04/08/20 | Boston |
| Sage Restructuring Halves Staff, Turns Focus to Failed Depression Drug | Frank Vinluan | 04/07/20 | Boston |
| Interactive, Online Xcelerating Life Sciences Boston Event Set for May 13 | Editors | 04/07/20 | Boston |
| GSK, Vir Team Up in COVID-19 Pact Aiming to Reach the Clinic in Months | Frank Vinluan | 04/06/20 | San Francisco |
| Xconomy Releases Coronavirus Special Report on Containing the Pandemic Through Innovation & Investment | Editors | 04/06/20 | Boston |
| Fate Inks $100M Deal With Janssen for Stem Cell-Derived Cancer Therapies | Sarah de Crescenzo | 04/03/20 | San Diego |
| Bio Roundup: Biotech Billions, COVID-19 R&D, Zolgensma’s Path & More | Sarah de Crescenzo | 04/03/20 | National |
| Flagship Adds $1.1B for New Meds, More AI, & “Health Security” | Sarah de Crescenzo | 04/02/20 | National |
| A Baby’s Milestones and the Next Steps for Novartis in Gene Therapy | Frank Vinluan | 03/31/20 | Raleigh Durham |
| Bio Roundup: Clinical Trials Paused, New MS Drug, Kallyope’s Cash & More | Frank Vinluan | 03/27/20 | National |
| FDA Approves Bristol Myers MS Drug, But Pandemic Will Delay Launch | Frank Vinluan | 03/26/20 | New York |
| AstraZeneca Joins RNAi Mix, Pledging $80M to Silence Therapeutics | Frank Vinluan | 03/25/20 | Europe |
| Kallyope Gains $112M to Move “Gut-Brain Axis” Programs to the Clinic | Sarah de Crescenzo | 03/25/20 | New York |
| CytomX Lands $80M to Kick Off Cancer Drug R&D Pact With Astellas | Frank Vinluan | 03/24/20 | San Francisco |
| Bio Roundup: Coronavirus Diagnostics, Therapeutics, Vaccines & More | Sarah de Crescenzo | 03/20/20 | National |
| As the Commercial Real Estate Market Slumps, Look for a More Tenant-Friendly Future | Editors | 03/19/20 | Boston |
| Fears Of Recession Mount As Coronavirus Declared A Pandemic | Andrew McConaghie | 03/19/20 | National |
| AbCellera’s Coronavirus “Neutralizing” Antibody Leads Enter Screening | Sarah de Crescenzo | 03/17/20 | National |
| Qiagen Juices RNA Extraction Kit Capacity to Feed Coronavirus Test Needs | Sarah de Crescenzo | 03/17/20 | National |
| The Benefits and Impact of Later In-Licensing Deals for Biopharma | Gareth Macdonald | 03/17/20 | National |
| UC San Diego Health Develops COVID-19 Test, Begins Testing Patients | Sarah de Crescenzo | 03/14/20 | San Diego |
| Bio Roundup: Pandemic Declared, Rubius Restarts, Kymera’s Cash & More | Frank Vinluan | 03/13/20 | National |
